Literature DB >> 2218531

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.

B A Yankner1, L K Duffy, D A Kirschner.   

Abstract

The amyloid beta protein is deposited in the brains of patients with Alzheimer's disease but its pathogenic role is unknown. In culture, the amyloid beta protein was neurotrophic to undifferentiated hippocampal neurons at low concentrations and neurotoxic to mature neurons at higher concentrations. In differentiated neurons, amyloid beta protein caused dendritic and axonal retraction followed by neuronal death. A portion of the amyloid beta protein (amino acids 25 to 35) mediated both the trophic and toxic effects and was homologous to the tachykinin neuropeptide family. The effects of the amyloid beta protein were mimicked by tachykinin antagonists and completely reversed by specific tachykinin agonists. Thus, the amyloid beta protein could function as a neurotrophic factor for differentiating neurons, but at high concentrations in mature neurons, as in Alzheimer's disease, could cause neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2218531     DOI: 10.1126/science.2218531

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  384 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.

Authors:  B Kaltschmidt; M Uherek; H Wellmann; B Volk; C Kaltschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 3.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

4.  Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.

Authors:  D R Howlett; A E Perry; F Godfrey; J E Swatton; K H Jennings; C Spitzfaden; H Wadsworth; S J Wood; R E Markwell
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

5.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

6.  Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein.

Authors:  Anthony R White; Gerd Multhaup; Denise Galatis; William J McKinstry; Michael W Parker; Rüdiger Pipkorn; Konrad Beyreuther; Colin L Masters; Roberto Cappai
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

7.  Transgene delivery with a cationic lipid in the presence of amyloid beta (betaAP) peptide.

Authors:  P S Ajmani; W Wang; F Tang; M A King; E M Meyer; J A Hughes
Journal:  Neurochem Res       Date:  2001-03       Impact factor: 3.996

8.  Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo.

Authors:  V V Trubetskaya; M Yu Stepanichev; M V Onufriev; N A Lazareva; V A Markevich; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2003-02

9.  A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.

Authors:  Yasuhiro Nakagami; Satoko Nishimura; Takako Murasugi; Isao Kaneko; Masaki Meguro; Shinji Marumoto; Hiroshi Kogen; Kazuo Koyama; Tomiichiro Oda
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 10.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.